Abstract
759P - Prognostic factors in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or bicalutamide (BIC) in TERRAIN
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have